RxDoctor Payments Data

Jennifer McLaughlin

Family · Colorado Springs, CONPI 1174726186

Payments from drug & device makers

$6,026in general payments, 2019–2025

Across 207 payments — averaging $29.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Johnson & Johnson$619
  • Novartis$563
  • Boston Scientific$457
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$434
  • Amgen$374
  • plus $2K from 25 others

What the payments were for

  • Consulting fees$250%
  • Travel & lodging$4888%
  • Food & beverage$5,43890%
  • Education$751%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,026 in reported general payments places this provider in the 95th percentile of 2,182 family providers in Colorado.

See all family providers in Colorado

Medicare billing

Part B allowed, 2024
$104,799
Medicare patients
501
Services billed
1,925

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban358$455,642
XareltoRivaroxaban114$146,237
MultaqDronedarone Hcl13$27,614
EntrestoSacubitril/Valsartan12$22,151
Flecainide Acetate196$9,729
Metoprolol Succinate336$4,894
SotalolSotalol Hcl104$2,190
Diltiazem 24hr Er (Cd)Diltiazem Hcl40$1,003
Potassium Chloride54$869
Amiodarone Hcl72$752
Carvedilol38$437
Atorvastatin Calcium45$369
Rosuvastatin Calcium13$299
Metoprolol Tartrate43$207
Amlodipine Besylate24$191

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$350$455,642358 claims
Johnson & JohnsonXarelto$619$146,237114 claims
Sanofi-aventis U.S. LLCMultaq$40$27,61413 claims
NovartisEntresto$563$22,15112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,182 family providers in Colorado.

Other family in Colorado Springs

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →